Aridis Pharmaceuticals, Inc. (ARDS)
OTCMKTS: ARDS · Delayed Price · USD
0.0010
-0.0090 (-90.00%)
Jul 25, 2024, 4:00 PM EDT - Market closed
Aridis Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Year Ending | TTM | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | 2017 - 2015 |
|---|---|---|---|---|---|---|---|
| Revenue | 22.36 | 3.09 | 1.54 | 1 | 1.02 | 2.76 | Upgrade
|
| Revenue Growth (YoY) | 680.42% | 101.37% | 53.50% | -2.15% | -62.93% | 220.58% | Upgrade
|
| Cost of Revenue | 17.15 | 25.7 | 36.94 | 16.96 | 24.08 | 23 | Upgrade
|
| Gross Profit | 5.21 | -22.61 | -35.4 | -15.96 | -23.06 | -20.24 | Upgrade
|
| Selling, General & Admin | 5.86 | 7.16 | 7.31 | 6.45 | 6.03 | 3.87 | Upgrade
|
| Operating Expenses | 5.86 | 7.16 | 7.31 | 6.45 | 6.03 | 3.87 | Upgrade
|
| Operating Income | -0.66 | -29.77 | -42.71 | -22.4 | -29.09 | -24.12 | Upgrade
|
| Interest Expense | - | -0.12 | -0.25 | - | - | - | Upgrade
|
| Interest & Investment Income | 0.18 | - | - | 0.08 | 0.36 | 0.42 | Upgrade
|
| Earnings From Equity Investments | - | - | - | -0.01 | -0.95 | -0.04 | Upgrade
|
| Other Non Operating Income (Expenses) | 0.1 | 0.09 | 0.07 | - | - | 1.63 | Upgrade
|
| EBT Excluding Unusual Items | -0.38 | -29.79 | -42.88 | -22.33 | -29.68 | -22.11 | Upgrade
|
| Asset Writedown | -0.23 | -0.23 | - | - | - | - | Upgrade
|
| Other Unusual Items | -0.54 | -0.35 | 0.69 | - | - | - | Upgrade
|
| Pretax Income | -1.14 | -30.37 | -42.19 | -22.33 | -29.68 | -22.11 | Upgrade
|
| Net Income | -1.14 | -30.37 | -42.19 | -22.33 | -29.68 | -22.11 | Upgrade
|
| Preferred Dividends & Other Adjustments | - | - | 4.13 | - | - | 1.36 | Upgrade
|
| Net Income to Common | -1.14 | -30.37 | -46.32 | -22.33 | -29.68 | -23.46 | Upgrade
|
| Shares Outstanding (Basic) | 32 | 19 | 12 | 9 | 8 | 3 | Upgrade
|
| Shares Outstanding (Diluted) | 32 | 19 | 12 | 9 | 8 | 3 | Upgrade
|
| Shares Change (YoY) | 88.34% | 52.77% | 34.06% | 8.40% | 168.80% | 1791.31% | Upgrade
|
| EPS (Basic) | -0.04 | -1.62 | -3.77 | -2.44 | -3.51 | -7.46 | Upgrade
|
| EPS (Diluted) | -0.04 | -1.62 | -3.77 | -2.44 | -3.51 | -7.46 | Upgrade
|
| Free Cash Flow | -17.93 | -29.21 | -23.47 | -20.84 | -8.33 | -24.95 | Upgrade
|
| Free Cash Flow Per Share | -0.56 | -1.56 | -1.91 | -2.27 | -0.99 | -7.93 | Upgrade
|
| Gross Margin | 23.28% | - | - | - | - | - | Upgrade
|
| Operating Margin | -2.93% | -962.99% | -2782.48% | -2240.10% | -2846.09% | -874.76% | Upgrade
|
| Profit Margin | -5.11% | - | - | - | - | - | Upgrade
|
| Free Cash Flow Margin | -80.21% | -944.97% | -1528.73% | -2084.30% | -815.36% | -904.90% | Upgrade
|
| EBITDA | -0.35 | -29.28 | -42.28 | -22.06 | -28.75 | -23.83 | Upgrade
|
| EBITDA Margin | -1.55% | - | - | - | - | - | Upgrade
|
| D&A For EBITDA | 0.31 | 0.49 | 0.44 | 0.34 | 0.34 | 0.28 | Upgrade
|
| EBIT | -0.66 | -29.77 | -42.71 | -22.4 | -29.09 | -24.12 | Upgrade
|
| EBIT Margin | -2.93% | - | - | - | - | - | Upgrade
|
| Revenue as Reported | 19.27 | - | - | - | - | 2.76 | Upgrade
|
Source: S&P Capital IQ. Standard template.